Evaluation of VCAM-1 and PAI-1 concentration in diabetes mellitus patients

Diabetologia Doswiadczalna i Kliniczna

Volumn 8, Issue 2, 2008, Pages 85-88

  Romuk, Ewa ^a   Jagosz, Jolanta ^b   Skrzep Poloczek, Bronisława ^a   Wojciechowska, Celina ^a   Strojek, Krzysztof ^a   Sȩdek, Łukasz ^a   Birkner, Ewa ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Medical College in Silesia   (Poland)

Author keywords

Atherosclerosis; Diabetes mellitus; Endothelial dysfunction; PAI 1; VCAM 1

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTERY ENDOTHELIUM; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SERODIAGNOSIS;

EID: 51949110763     PISSN: 16433165     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Meigs JB, Hu FB, Rifai N, Manson JE. Biomarkers of endothelial dysfunction ad risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-1986.
2. Tousoulis D, Davies G, Stefanadis C, Toutmbrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003: 89: 993-997.
3. Fattah MA, Shaheen MM, Mahfou MH. Disturbances of haemostasis in diabetes mellitus. Dis Markers 2003; 19: 251-258.
4. Lyon ChJ, Hsueh WA. Effect of Plasminogen Activator Inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003; 115: 62-68.
5. Theuma P, Fonseca VA. Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis. Curr Diab Rep 2003; 3: 248-254.
6. Biondi-Zoccari GG, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003; 41: 1071-1077.
7. Rizzoni D, Porteri E, Guelfi D. et al. Endothelial dysfunction in small resistance arteries of patients with non-insulin-dependent diabetes mellitus. J Hypertens 2001; 19: 913-919.
8. Kowalska I, Stra̧czkowska M, Szelachowska M. et al. Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism. Metabolism 2002; 51: 733-736.
9. Matsumoto K, Sera Y, Ueki Y Inukai G, Niiro E, Miyake S. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 2002; 19: 822-826.
10. Weissberg P. Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. Atherosclerosis 1999; 147: 3-10.
11. Vaughan D. PAI-1 and atherothrombosis. J Thromb Haemost 2005; 3: 1879-1883.
12. Aldhahi W, Handy O. Adipokines, inflammation and the endothelium in diabetes Curr Diab Rep 2003; 3: 293-298.
13. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ. Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric-oxide synthase inhibition. Circulation 2001; 104: 839-844.
14. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase protein and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 2002; 51: 1131-1137.
15. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to Incident type 2 diabetes. Circulation 2006; 113: 1753-1759.
16. Leurs PB, Stolk RP, Hamulyak K, Van-Oerle R, Grobbee DE, Wolffenbuttel BH. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in eldery individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002; 25: 1340-1345.
17. Meigs JB, O'donnell CJ, Toiler GH. et al. Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes 2006: 55: 530-537.
18. Schafer K, Muller K, Hecke A, Mounier E. et al. Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1 . Arterioscler Thromb Vasc Biol 2003; 23: 2097-2103.
19. de Maat MPM, Bladbjerg T, Drivsholm T. Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. J Thromb Haemost 2003; 1: 950-957.
20. Folsom AR. Fibrinolytic factors and atherothrombotic events: epidemiological evidence. Ann Med 2000; suppl 1: 85-91.
21. Bluher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or type 2 diabetes. Diabetologia 2002; 45: 210-216.
22. Boulbou MS, Koukoulis GN, Makri ED. et al. Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Int J Cardiol 2005; 98: 39-44.